Literature DB >> 3379548

Association of closure of patent ductus arteriosus and development of necrotizing enterocolitis.

S B Palder1, M Z Schwartz, K R Tyson, C C Marr.   

Abstract

Over a 5-year period ending in June 1986, 234 neonates with evidence of a significant patent ductus arteriosus (PDA) underwent ductal manipulation. Thirty-four infants (15%) developed evidence of necrotizing enterocolitis (NEC). When NEC and treatment of PDA were within 72 hours of each other, there was a 71% mortality rate. When NEC and PDA ligation were greater than 72 hours apart, there were no deaths. Development of NEC prior to ductal closure was associated with a mortality of 57%, as opposed to no mortality when the development of NEC occurred after ductal closure. Our data suggest that infants who develop NEC before PDA ligation incur a high mortality.

Entities:  

Mesh:

Year:  1988        PMID: 3379548     DOI: 10.1016/s0022-3468(88)80439-1

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

Review 1.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

2.  Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons.

Authors:  Donald McCurnin; Ronald I Clyman
Journal:  Pediatrics       Date:  2008-11-10       Impact factor: 7.124

3.  Pharmacological closure of the patent ductus arteriosus.

Authors:  Sk Mehta; A Younoszai; J Pietz; Bp Achanti
Journal:  Images Paediatr Cardiol       Date:  2003-01

4.  Primary peritoneal drainage in neonates with necrotizing enterocolitis associated with congenital heart disease: a single experience in a Brazilian tertiary center.

Authors:  W C Canesin; F A P Volpe; W A Gonçalves-Ferri; P H Manso; D C Aragon; L Sbragia
Journal:  Braz J Med Biol Res       Date:  2021-05-31       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.